Want to see WGRX full AI Analyst Report?
WGRX Stock Chart & Stats
$0.14
--
Market closed
$0.14
--
Day’s Range― - ―
52-Week Range$2.80 - $97.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.82M
Market Cap
$7.57M
Enterprise Value$38.16M
Total Cash (Recent Filing)$51.73K
Total Debt (Recent Filing)$28.91M
Price to Earnings (P/E)―
Beta0.72
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,647,198
10 Day Avg. Volume1,367,507
30 Day Avg. Volume28,820,997
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap5.04
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit-3.93
Enterprise Value/Ebitda-0.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI & Blockchain PlatformWellgistics is pursuing an integrated AI and blockchain healthcare infrastructure combining EinsteinRx, PharmacyChain and Datavault licenses. Owning data verification and exchange layers can create durable network effects, proprietary data assets and differentiated service barriers if execution and adoption persist.
Joint Venture Expanding Patient ReachA 51% stake in the Healthstar JV expands direct-to-patient and telepharmacy channels, giving sustained access to patient volumes and routing benefits. Controlling the operational hub supports longer-term revenue diversification, tighter pharmacy network integration and scale advantages if integration delivers operational synergies.
Capital Raise Improving Near-term LiquidityThe private convertible note financing generated material cash proceeds and funded partial debt repayment, easing immediate liquidity pressure. While conversion and warrants introduce dilution risk, the deal materially lengthens runway and reduces default risk, enabling continued execution on strategic integrations and product development.
Bears Say
Sharp Revenue And Margin DeclineRevenue contraction and deeply negative gross and net margins indicate the core distribution and platform economics are not yet viable. Persistent negative unit economics suggest pricing, COGS control or mix challenges that will impair long-term self-funding and require sustained external capital until operations materially improve.
Negative Shareholders' EquityNegative equity with substantial debt weakens financial flexibility, raises refinancing and covenant risks, and contributed to Nasdaq equity-compliance scrutiny. This capital-structure deterioration constrains strategic options, increases cost of capital, and creates a durable solvency overhang until equity is rebuilt or debt reduced.
Ongoing Cash BurnLarge negative operating and free cash flows show the business currently consumes cash to operate and invest. Continued burn forces repeated dilutive financings or costly debt arrangements, raising execution risk on strategic initiatives and putting long-term viability contingent on achieving positive operating leverage.
Wellgistics Health Inc News
WGRX FAQ
What was Wellgistics Health Inc’s price range in the past 12 months?
Wellgistics Health Inc lowest stock price was $2.80 and its highest was $97.50 in the past 12 months.
What is Wellgistics Health Inc’s market cap?
Wellgistics Health Inc’s market cap is $7.57M.
When is Wellgistics Health Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Wellgistics Health Inc’s earnings last quarter?
Currently, no data Available
Is Wellgistics Health Inc overvalued?
According to Wall Street analysts Wellgistics Health Inc’s price is currently Overvalued.
Does Wellgistics Health Inc pay dividends?
Wellgistics Health Inc does not currently pay dividends.
What is Wellgistics Health Inc’s EPS estimate?
Wellgistics Health Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wellgistics Health Inc have?
Wellgistics Health Inc has 2,647,198 shares outstanding.
What happened to Wellgistics Health Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Wellgistics Health Inc?
Currently, no hedge funds are holding shares in WGRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wellgistics Health Inc
Wellgistics Health, Inc. functions as a primary wholesaler and distributor of pharmaceutical products throughout the United States, catering to both drug manufacturers and independent retail pharmacies. Its extensive product catalog includes a variety of generic and brand-name pharmaceuticals, alongside over-the-counter healthcare and consumer merchandise. The company also delivers a suite of third-party logistics (3PL) services, encompassing warehousing, inventory control, pick-and-pack operations, and shipping solutions, specifically designed for small to mid-sized pharmaceutical producers. Furthermore, Wellgistics manages the DelivMeds platform, an integrated pharmaceutical hub that streamlines prescription transfers and offers essential backend clinical concierge support to its network of independent pharmacies. It also runs a specialized retail community service. Established in 2022 and headquartered in Tampa, Florida, the organization adopted its current name, Wellgistics Health, Inc., in October 2024, having previously operated as Danam Health, Inc.
Technical Analysis
―
Prestige Consumer Healthcare
―
―
Synergy CHC
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
20.40% Insiders
17.09% Mutual Funds
― Other Institutional Investors
62.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---